Cancer FDA accepts Keytruda head and neck cancer filing Merck's PD-1 inhibitor Keytruda (pembrolizumab) has been accepted for priority review by the FDA in another new setting, head and neck cancer.
News Novo sues Lilly over 'misleading' GLP-1 ad campaigning The rivalry between Novo Nordisk and Eli Lilly in the GLP-1 market has spilled over into the courts in the US, with claims of misleading advertising.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
